Search
for
Sort by
Research 31–60 of 1000+
- Inhibitory Effects of Pueraria mirifica Aqueous Extracts on 5α-reductase and Prostate Histomorphometry in Testosterone-induced Benign Prostatic Hyperplasia Sprague Dawley Rats
- Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
- Faculty Opinions recommendation of Androgenetic alopecia as an early marker of benign prostatic hyperplasia.
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- Herbs for Benign Prostatic Hyperplasia
- Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review
- Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Androgenetic alopecia as an early marker of benign prostatic hyperplasia
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia
- Dutasteride for the treatment of benign prostatic hyperplasia
- Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the Male
- Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
- 5α‐Reductase inhibitors and prostatic disease
- Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride
- Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
- Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
- Corn silk extract improves benign prostatic hyperplasia in experimental rat model
- Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia